Key references: Nonresponse to initial pharmacotherapy for obsessive compulsive disorder in adults and young people

  • Albert U, Carmassi C, Cosci F, De Cori D, Di Nicola M, Ferrari S, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol 2016;31(5):249–58. https://www.ncbi.nlm.nih.gov/pubmed/26974213
  • Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(5):403–39. https://www.ncbi.nlm.nih.gov/pubmed/24713617
  • Brakoulias V, Stockings E. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert Opin Pharmacother 2019;20(1):47–53. https://www.ncbi.nlm.nih.gov/pubmed/30360669
  • Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 2015;18(9). https://www.ncbi.nlm.nih.gov/pubmed/25939614
  • Fineberg NA, Baldwin DS, Drummond LM, Wyatt S, Hanson J, Gopi S, et al. Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder. Int Clin Psychopharmacol 2018;33(6):334–48. https://www.ncbi.nlm.nih.gov/pubmed/30113928
  • Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14 Suppl 1:S1. https://www.ncbi.nlm.nih.gov/pubmed/25081580
  • Kim D, Ryba NL, Kalabalik J, Westrich L. Critical review of the use of second-generation antipsychotics in obsessive-compulsive and related disorders. Drugs R D 2018;18(3):167–89. https://www.ncbi.nlm.nih.gov/pubmed/30171515
  • Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A. The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep 2017;19(12):103. https://www.ncbi.nlm.nih.gov/pubmed/29110139
  • Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry 2014;14:317. https://www.ncbi.nlm.nih.gov/pubmed/25432131
  • Zhou DD, Zhou XX, Li Y, Zhang KF, Lv Z, Chen XR, et al. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2019;90:277–87. https://www.ncbi.nlm.nih.gov/pubmed/30576763